Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. (DTIL) on April 15, 2021, covering events occurring on April 14, 2021. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market. The filing primarily addresses executive leadership changes within the medical division.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific compensatory arrangement for a departing officer:
- Consulting Fee: $600 per hour.
- Maximum Fee Cap: $35,000 under the new Consulting Agreement.
Material Changes
The primary material change reported is the departure of Christopher Heery, M.D., as Chief Medical Officer (CMO), effective April 23, 2021. He is being succeeded by Alan List, M.D., who was previously serving as a strategic clinical advisor. Dr. List's appointment as CMO is effective April 26, 2021.
Management Commentary and Contingencies
In connection with Dr. Heery's resignation, the company expects to enter into a Consulting Agreement. Key terms include:
- Dr. Heery will provide consulting services for an hourly fee.
- Stock options held by Dr. Heery will continue to vest during the term of the agreement.
- Dr. Heery is entitled to an extended post-termination exercise period for his options.
The company issued a press release on April 15, 2021, announcing Dr. List's appointment, which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the effective dates of the CMO transition (April 23 departure, April 26 appointment).
- Confirm the final terms of the Consulting Agreement with Dr. Heery, specifically regarding the vesting schedule and option exercise period.
- Review the press release (Exhibit 99.1) for additional details on Dr. List's background and strategic role.
- Note that this filing contains no new financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.